
Summer heat increases risk of child deaths in hot cars, advocates warn
Interview with Janette Fennell of Kids and Car Safety on protecting children from hot cars
A record heat wave that spread across the East Coast of the United States during the first week of summer has child advocates warning parents and caretakers about the risks of heatstroke to children left inside hot vehicles.
So far this year, nine children have died after being left unattended in vehicles in California, Florida, Louisiana, Maryland, New Mexico, New Jersey and North Carolina, according to Kids and Car Safety, which collects data on hot car deaths. Five died in June.
According to data from advocacy group Kids and Car Safety, on average, 38 children die each year from heatstroke inside a vehicle. Since 1990, at least 1,134 children have died in hot cars in the United States and at least another 7,500 survived with varying degrees of injury, according to data compiled by Kids and Car Safety.
Why hot cars are so dangerous for kids
Human-caused climate change keeps dialing up temperatures and extreme weather, scientists say. But the temperature outside doesn't have to be super hot for a child left in a vehicle to be affected by the heat, said Kathy Wall, director of Safe Kids Palm Beach County.
"Inside, the vehicle can heat up 20 degrees in just 20 minutes," Wall said. "So if you imagine it's an 80 degree day, which in South Florida is a cool day, it could be over 100 degrees within 10 minutes inside the car."
Hot car deaths can happen any time of year, and since 1998, every state but Alaska has reported a hot car death, according to the National Safety Council. In both 2018 and 2019, a record 53 children died after being left in hot cars.
About 80% of the heat rise in vehicles happens in the first 30 minutes of a child being left inside, when maximum temperatures can exceed 150 degrees Fahrenheit (65 degrees Celsius), according to data compiled by Jan Null, a certified consulting meteorologist at San Jose State University.
"Children sweat a lot less than adults do and their internal temperature can increase three to five times faster than an adult. So that's why it's just as important to make sure that your child isn't left in the vehicle, especially during these rising temperatures," said Capt. Karen Derogatis of Palm Beach County Fire Rescue.
Last week, a 5-year-old boy in Mansfield, Ohio, died after being left in a hot vehicle.
It can happen to anyone
While it's easy to place blame for leaving a child in a vehicle, even people trained to know the dangers have made that tragic mistake, Wall said.
"It's not a socioeconomic group, it's not a cultural group," she said. "This sadly has happened to doctors, it's happened to dentists, it happened to school teachers, it's happened to child care workers. Nobody is exempt from this."
Distraction often leads to forgetting about a child in the backseat, which is why it is important to create routines and reminders, she said.
"It sounds crazy, but sometimes people get out of routines or are distracted, especially in today's world. There's lots going on in the news, lots going with families," she said.
A parent who normally doesn't drop a child off at a day care facility might become distracted and forget that the child is in the vehicle, she said.
Create a reminder that a child is in the backseat
She encourages parents and caregivers to establish routines.
"We have an acronym, ACT," Wall said.
"A" stands for avoiding leaving a child unattended in a vehicle. "C" stands for creating a reminder that works best for you. Authorities suggest leaving a personal item such as a purse or briefcase in the backseat so you'll have to open the back door before locking the vehicle. "T" is to take action right away.
"If you see a child in a car, don't try to figure out how long they've been in the car. Call 911 immediately," Wall said.
Some newer cars offer warnings for drivers to check the backseat for passengers.
Double checking the vehicle is key, said Derogatis, the fire captain.
"If you make it a common habit, just like you would look in their rear view mirror to see if somebody's behind you, or if you look at your side view mirror to see if you want to switch lanes, make it habit to look in your rearview mirror, whether you have a child or an animal or anything, just to ensure that they are as safe as possible," she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Goldman Sachs Reaffirms 'Buy' Rating on Iovance (IOVA) for Positive Amtagvi Data
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 best healthcare penny stocks to buy according to analysts. Goldman Sachs reiterated its 'Buy' rating on Iovance's stock on June 3. The firm also maintained its $34.00 price target for Iovance shares. A close up of a lab technician in a protective suit, working with cells in a petri dish to develop innovative therapeutics for immune-related diseases. Goldman Sachs based its reaffirmation on new data that Iovance presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO data focused on Amtagvi, a tumor-infiltrating lymphocyte (TIL) therapy. The FDA approved the treatment in February 2024 for adult patients with unresectable or metastatic melanoma. The data supported the therapy's safety profile, which, according to Goldman Sachs, reinforces Amtagvi's potential as a significant treatment option. Goldman Sachs's analysts noted that the five-year follow-up data are unprecedented for any therapy in this heavily pretreated advanced melanoma population. To them, the data highlights the durability of Amtagvi's responses. The firm emphasized Amtagvi's successful US launch, with consistent patient demand, enhanced operations at Authorized Treatment Centers (ATCs), and improved out-of-spec rates (manufacturing quality metrics). It also highlighted the drug's first full calendar year of sales in 2025 as a key driver. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company. It develops and markets cell therapies that harness a patient's own immune cells to treat solid tumors. Its lead product is Amtagvi, approved for advanced melanoma, and it also markets Proleukin. Iovance's pipeline includes candidates for cervical cancer, non-small cell lung cancer, and hematologic malignancies. While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company reported that it had granted options to purchase an aggregate of 137,000 shares of its common stock to three newly hired employees on May 30, 2025. yezry/ These options were given as inducement material to each employee entering into employment with Akebia. The company stated that the grants were made per Nasdaq Listing Rule 5635(c)(4). Also, the exercise price for the options is $3.03 per share, which was the closing price of the company's common stock on the grant date. The stock options vest over a four-year period, with 25% of the shares vesting on the first anniversary of the grant date. The remaining 75% will vest quarterly thereafter, provided the new employee remains with Akebia. The options are the latest after Akebia granted 148,000 shares of its common stock to eight newly hired employees on April 30, 2025. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing treatments for kidney-related diseases. It develops and sells two main products: Auryxia, used to manage phosphorus levels and treat iron deficiency anemia in patients with chronic kidney disease (CKD), and Vafseo, an oral medication for anemia associated with CKD. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
Maravai LifeSciences (MRVI) Undergoes Leadership Overhaul Amid Transition
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 26, William Blair reaffirmed its 'Market Perform' rating for Maravai stock. The key factor influencing this move is the leadership changes at Maravai. A scientist performing a blood test on a patient using life sciences tools & services. Maravai has undergone a complete leadership overhaul since December last year. In December 2024, the company brought in Andy Eckert as the new independent Chairman of the Board. Later, Maravai installed Bernd Brust as CEO, replacing Trey Martin. Then, on June 25, a new press release indicated that Rajesh 'Raj' Asarpota would assume the position of Executive Vice President and Chief Financial Officer, effective June 30. According to William Blair, Brust and Asarpota are joining Maravai's top-level management when the company is undergoing 'a challenging operational transition period.' The analysts noted that the company 'faces approximately $66 million in headwinds in 2025 from declining COVID-related revenues.' As such, the analysts are optimistic that the fresh hands at Maravai's helm will inject more momentum into the transition. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is a life sciences company. It provides specialized products that support the development of vaccines, drug therapies, diagnostics, and cell and gene therapies. Its operations span two segments: Nucleic Acid Production and Biologics Safety Testing. While we acknowledge the potential of MRVI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data